Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours ; volume:73 ; number:5 ; day:30 ; month:3 ; year:2024 ; pages:1-9 ; date:5.2024
Cancer immunology immunotherapy ; 73, Heft 5 (30.3.2024), 1-9, 5.2024

Creator: Patel, Manish R.
Johnson, Melissa
Winer, Ira
Arkenau, Hendrik-Tobias
Cook, Natalie
Samouëlian, Vanessa
Aljumaily, Raid
Kitano, Shigehisa
Duffy, Christine
Ge, Miaomiao
Elgadi, Mabrouk
Siu, Lillian L.

Contributor: SpringerLink (Online service)

DOI: 10.1007/s00262-024-03654-0

URN: urn:nbn:de:101:1-2407090921472.159479825476

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:48 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Patel, Manish R.
Johnson, Melissa
Winer, Ira
Arkenau, Hendrik-Tobias
Cook, Natalie
Samouëlian, Vanessa
Aljumaily, Raid
Kitano, Shigehisa
Duffy, Christine
Ge, Miaomiao
Elgadi, Mabrouk
Siu, Lillian L.
SpringerLink (Online service)

Other Objects (12)

Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial

Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells

Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors

Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies

Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial

Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody

Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models

Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)- LLO immunotherapy

Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial

Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells

Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors

Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies

Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial

Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody

Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models

Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)- LLO immunotherapy

Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial

Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells

Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors

Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies

Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial

Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody

Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models

Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)- LLO immunotherapy

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial

Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells

Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors

Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies

Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial

Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody

Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models

Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)- LLO immunotherapy

Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial

Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells

Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors

Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies

Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial

Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody

Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models

Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)- LLO immunotherapy

Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial

Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells

Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors

Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies

Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial

Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody

Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models

Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)- LLO immunotherapy

Related objects

Reset password